<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295086</url>
  </required_header>
  <id_info>
    <org_study_id>Her-TEX</org_study_id>
    <nct_id>NCT01295086</nct_id>
  </id_info>
  <brief_title>Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer</brief_title>
  <official_title>Dose Determination of Taxotere®, Eloxatin® and Xeloda® (TEX)in Combination With Herceptin® as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this dose-finding study is to determine the maximum tolerated dose of
      taxotere, eloxatin and capecitabine (TEX) in combination with herceptin given every third
      week as first-line treatment in patients with HER2-positive advanced gastro-esophageal
      cancer. Secondary end points are to evaluate progression-free survival and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aim:

      To define the maximum tolerated dose of the combination of taxotere, eloxatin and
      capecitabine (TEX) in combination with herceptin given every third week as first- line
      treatment in patients with HER2-positive advanced gastro-esophageal cancer.

      Secondary aims:

      Estimating response-rate, progression free survival and overall survival

      Methods:

      This dose-finding study is planned to include 15 patients with HER2 positive
      gastro-esophageal cancer, adenocarcinoma. Patients will be included in cohorts of three at
      progressively higher dose levels.

      Chemotherapy will be repeated day 1 every third week to a maximum of eight cycles. Treatment
      with trastuzumab will continue until disease progression. Dose-limiting toxicity (DLT) will
      be evaluated after the first cycle. In case of DLT among one of the three patients during the
      first course of treatment additional three patients will be added at the respective dose
      level. Dose escalation is continued if 0/3 or 1/6 patients experience DLT.

      Patients will be evaluated with a ct- scan at baseline and after every three cycles to
      exclude progression and evaluate response. Response is assessed by investigators according to
      RECIST version 1.1.

      Blood counts regarding tumour biology will be collected at baseline before 2nd, 4th and 7th
      cycle and 4 weeks after ended treatment. After completion of treatment patients will be
      followed every third month until progression or death.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine maximum tolerable dose (MTD) for the combination regime TEX</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators have planned to examine 3 dose levels including 3 patients at each level with escalating doses of docetaxel from 42 mg/m² to 60 mg/m² and fixed doses of oxaliplatin (100 mg/m²), capecitabine 625 mg/m² x 2 and trastuzumab 6 mg/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from inclusion to disease progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Time from inclusion to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
    <description>According to RECIST version 1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Her-TEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>42, 51 or 60 mg/m² day 1 every 3. week</description>
    <arm_group_label>Her-TEX</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>100 mg/m² day 1 every 3. week</description>
    <arm_group_label>Her-TEX</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1250 mg/² continuously</description>
    <arm_group_label>Her-TEX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week</description>
    <arm_group_label>Her-TEX</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven ECV-adenocarcinoma, non-resectable or metastatic
             disease

          2. HER2-positive tumor tissue (IHC 3 + or FISH positive)

          3. LVEF &gt; 50 % (MUGA scan or echocardiography)

          4. Age ≥ 18 years

          5. No prior chemotherapy

          6. WHO performance status 0-1

          7. Life expectancy of at least 3 months

          8. Neutrophils ≥ 1.5 x 109/L and platelets ≥ 100 x 109/L

          9. Bilirubin ≤ 1.5 x UNL (Upper Normal Limit) and ASAT and/or ALAT ≤ 3 x UNL. In case of
             liver metastases no UNL for ASAT and ALAT

         10. Creatinine clearance ≥ 50 ml/min. Calculated with the Cockroft-Gault formula

         11. No neuropathy

         12. Planned treatment start within 8 days after inclusion

        Exclusion Criteria:

          1. Patients who cannot complete treatment or evaluation

          2. Any condition or treatment which after the opinion of the investigator may expose the
             patients to a risc or influence the purpose of the study

          3. Known hypersensitivity towards any of the study drugs

          4. Other malignant disease within the last 5 days, except for non-melanoma skin cancer

          5. Other serious disease (e.g. cardiac disease, AMI within 1 year or infection)

          6. Pregnant women or nursing women

          7. Physical or mental conditions which may prevent absorption of oral treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per Pfeiffer, Professor</last_name>
    <phone>+45 6541 2921</phone>
    <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrine Rahbek Schønnemann, MD</last_name>
    <phone>+45 6541 2921</phone>
    <email>k.shoennemann@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Yilmaz, MD</last_name>
      <phone>+45 9932 1111</phone>
    </contact>
    <investigator>
      <last_name>Mette Yilmaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Ladekarl, MD</last_name>
      <phone>+45 8949 4444</phone>
    </contact>
    <investigator>
      <last_name>Morten Ladekarl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene Bæksgaard, MD</last_name>
      <phone>+45 3545 3545</phone>
    </contact>
    <investigator>
      <last_name>Lene Bæksgaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrine Rahbek Schoennemann, MD</last_name>
      <phone>+45 6541 2921</phone>
      <email>k.schoennemann@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Katrine Rahbek Schoennemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adenocarcinoma of the gastro-esophageal</keyword>
  <keyword>Her2</keyword>
  <keyword>Dose finding</keyword>
  <keyword>Taxotere (Docetaxel)</keyword>
  <keyword>Eloxatin (Oxaliplatin)</keyword>
  <keyword>Xeloda (Capecitabine)</keyword>
  <keyword>Herceptin (Trastuzumab)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

